Laura Ryan, MD
Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1619984416
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $113,446 of the $126,252 with a category attached, or 89.9%. Amgen accounts for 85.5% of it on its own, with 1 other manufacturer making up the rest. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $1202.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$108K
- Ascendis Pharma Endocrinology Inc$18K
What the payments were for
- Speaking & faculty fees$113,44690%
- Travel & lodging$11,5799%
- Food & beverage$1,1381%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 91 | $108,002 |
| Ascendis Pharma Endocrinology Inc | 14 | $18,250 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$126,252 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriparatide | 15 | $72,103 |
| OzempicSemaglutide | 39 | $68,309 |
| JardianceEmpagliflozin | 36 | $47,722 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $17,400 |
| SynthroidLevothyroxine Sodium | 168 | $13,449 |
| GenotropinSomatropin | 12 | $12,751 |
| FarxigaDapagliflozin Propanediol | 25 | $10,061 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $8,664 |
| Liothyronine Sodium | 157 | $7,571 |
| Novolog FlexpenInsulin Aspart | 19 | $7,564 |
| TirosintLevothyroxine Sodium | 20 | $4,911 |
| Desmopressin Acetate | 31 | $4,439 |
| Hydrocortisone | 58 | $3,575 |
| Levothyroxine Sodium | 510 | $3,454 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $2,191 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Columbus
- Elena ChristofidesColumbus$2.3M
- Samuel AndersonColumbus$556K
- Ravi DhawaleColumbus$175K
- Kathleen WyneColumbus$88K
- Kathleen DunganColumbus$60K
- Jay PatelColumbus$60K
- Lawrence KirschnerColumbus$57K
- Shrikant TamhaneColumbus$55K
- Constantine KroustosColumbus$53K
- Laura ButzColumbus$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.